Strategy

Apr 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
MVPs go beyond numbers to create extraordinary value for companies and their stockholders. They are the top two to five percent of employees. In other words, if you were to lose 100 people, which two to five would you protect at all costs?
Apr 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
You can have a biotech company with a great technology base, but if it doesn't have a product in Phase II development, Wall Street won't reward the company by increasing the value of its stock price. When products are valued over technology, there is a higher premium for commercially-focused business leaders.
Apr 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
For the third year in a row, Abbott Labs has made it into the top 10 companies judged by DiversityInc magazine to have the most diverse workforce. According to DiversityInc co-founder Luke Visconti, that makes Abbott, number five in the ranking, extraordinary. Merck is the only other pharma company to make the cut, but comes in at number 24, and is on a downturn—it was ranked 13 last year.
Apr 01, 2005
Pharmaceutical Executive
Contrary to myth, Paragraph IV certifications are not reserved only for blockbusters or high-volume primary care products. Three products under recent Paragraph IV challenges had sales of less than $50 million.
Apr 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
World-class talent seeks its own level, so hiring companies should make sure that those involved in the interviewing process are strong employees who represent the company as leaders in their own rights.
Apr 01, 2005
Pharmaceutical Executive
Every quarter, pharmaceutical manufacturers confront a dizzying array of price reporting obligations. Participation in the Medicare, Medicaid, Veterans Administration (VA), and Public Health Service (PHS) programs requires manufacturers to collect, organize, distill and manipulate vast quantities of information, and to generate from that data reportable figures that can have an enormous impact on the company's bottom line. It is critical that these figures be correct, not only to help ensure the integrity of these public programs, but because submission of false data to a federal agency is a prosecutable criminal offense, and the civil penalties and exposure can be staggering.
Apr 01, 2005
Pharmaceutical Executive
Conventional wisdom says that generics businesses are a drain on valuable resources. But these units are much less prone to the disastrous drug safety panics that Big Pharma has recently endured.
Apr 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Institutions bring value to industry not only through shared coursework or customized training programs, but also through leveraging the intellectual property of institutional personnel for corporate problem solving.
Apr 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
It is unethical for a retained search firm to fill one client's needs by poaching people from another client that entrusts the firm with its searches and secrets. Partnering—and sharing fees—might be the solution.
Apr 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Job candidates that evangelize a company are worth more than PR campaigns.
native1_300x100
lorem ipsum